£1.8M
Mercia Ventures led the seed financing round with participation from several backers to support platform validation and team growth.
Kuano
Kuano combines quantum mechanics and AI to design targeted enzyme inhibitors.
£2.8MTotal raised
Kuano is a drug discovery enterprise that merges quantum mechanics with artificial intelligence to engineer next-generation medicines targeting enzymes. Based in Cambridge, the firm develops simulation platforms to model enzyme behaviour for precision drug design.
Filed accounts
Net current assets
Members only
Total assets less current liabilities
Members only
Net assets
Members only
Shareholders' funds
Members only
Fixed assets
Members only
Current assets
Members only
Cash, assets and headcount from Kuano's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Categories
Founders
VS
Vid Stojevic
Co-founder and CEO
Vid is the co-founder and chief executive of Kuano, following previous co-founding and technical leadership roles at GTN. His background includes academic research positions at University College London, the University of Gent, and the University of Vienna.
LinkedIn
David Wright
Co-founder
David brings computational chemistry and molecular modelling experience from roles at UCL, Ensemblemd, and GTN, alongside his current position as co-founder and CTO at Kuano.
LinkedIn
Parminder Ruprah
Co-founder
Parminder brings medicinal chemistry and drug discovery experience from roles at Kuano, GTN, and Takeda Cambridge.
LinkedInJD
Jarryl D’Oyley
Co-founder
Investors
- £1.8M
- £1.0M
Funding history
£1.0M
The seed round was backed by ACF Investors, o2h Ventures, and angel investors to fund team expansion and platform development.